Organisation paid for research Program year 2025 Source: CMS Open Payments

Cognitive Clinical Trials, LLC

Neither a doctor nor a teaching hospital

Research payments

$8,243,607

443 payments

Through program year 2025, Cognitive Clinical Trials, LLC is reported as receiving $8,243,607 in research payments, across 443 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $281,699 51
2024 Research $1,442,453 124
2023 Research $1,633,961 122
2022 Research $4,848,187 140
2021 Research $19,213 2
2020 Research $18,094 4

Breakdown

Who paid Research payments · program years 2020–2025
  1. Moderna TX, Inc. $4,612,763 90 payments
  2. Seqirus USA Inc $2,711,098 182 payments
  3. Sage Therapeutics, Inc. $285,137 8 payments
  4. Organon LLC $171,362 38 payments
  5. Alnylam Pharmaceuticals Inc. $159,957 62 payments
  6. Sun Pharmaceutical Industries Inc. $131,885 42 payments
  7. Merck Sharp & Dohme Corporation $120,492 8 payments
  8. Avanir Pharmaceuticals, Inc. $28,147 9 payments
  9. Urovant Sciences Inc $19,000 3 payments
  10. Sumitomo Pharma America, Inc. $3,766 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $4,190,434 22 payments
  2. Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/?or H5N6 Influenza Vaccine in Adults $2,446,211 130 payments
  3. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $232,727 28 payments
  4. A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age $220,887 44 payments
  5. Phase 1/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 candidate seasonal influenza vaccine in healthy adults 18 years and older $160,202 25 payments
  6. A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) $159,146 5 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $125,992 3 payments
  8. A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $120,412 7 payments
  9. Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata $117,447 39 payments
  10. Og-8175A-023 $91,509 17 payments
What the money was spent on Research payments · program years 2020–2025
  1. Patient care $171,362 38 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record